AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02144493 — intervention group
Intervention type: OTHER
Intervention: The existence of periampullary diverticulum
Description: Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.
Study NCT02144493 — intervention group
Intervention type: OTHER
Intervention: CBD angle
Description: Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
Study NCT01051622 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Labeling Ceretec
Description: Technetium-99m is used to radiolabel cells of interest i.e PBMC's
Study NCT03229382 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
Study NCT01907724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDX719
Description: IDX719 will be supplied as a 50 mg tablet for oral administration.
Study NCT01907724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 mg capsules for oral administration.
Study NCT01907724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: TMC647055 will be supplied as 150 mg capsules for oral administration.
Study NCT01907724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Description: RTV will be supplied as 80 mg/mL solution for oral administration.
Study NCT00700284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vaginal ring
Description: vaginal ring containing no TMC120 (dapivirine)
Study NCT00700284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC120 (dapivirine) vaginal ring
Description: vaginal ring containing 120 mg TMC120 (dapivirine)
Study NCT01848652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion of MYOCET
Study NCT03047954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Description: BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)
Study NCT03047954 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - Cap
Description: Matching Placebo capsule administered
Study NCT02599883 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low-Dose Computed Tomography
Description: Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
Study NCT00703378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel (Taxotere®)
Description: Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
Study NCT02838290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction
Description: Participants will be randomly assigned (computer generated straight away after clicking the link to the research) to one of 4 experimental conditions: stress at work, dealing with a patient's death, managing stress at work or all topics together. Each module includes brief reflection parts and quizzes. Participants will be asked to fill in an online survey just before the induction and a week after. The survey is about current occupational distress and organizational factors.
Study NCT02838290 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Participants in the control group will be asked to fill in an online survey, but will not have any task at time-1. However, participants in the control group will be invited to complete induction programme after time-2 (a week time after time-1) in ensure the same expectations in both, experimental and control, groups.
Study NCT02878278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide BIW
Description: Chidamide is given 30mg, twice a week
Study NCT02878278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide QD
Description: Chidamide is given 10mg,QD
Study NCT02866019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLS2702C/CLS2702D
Description: CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month \[4 weeks\]; cell sheet culture period, 0.5 month \[16 days\]; transplantation period, assessment/follow-up period, 6 months \[24 weeks\])
Study NCT02958878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Study NCT02958878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Study NCT02722824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-stimulation
Study NCT02722824 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Electro-stimulation
Study NCT02722824 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00804349 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Autotitrating Positive Airway Pressure
Description: Patients will be treated with Autotitrating Positive Airway Pressure therapy
Study NCT04372966 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Total hip arthroplasty
Description: Corail Total hip arthroplasty system, Depuy. Exeter and Contemporary acetabular components, Stryker.
Study NCT03525353 — intervention group
Intervention type: OTHER
Intervention: Endoscopic retrograde cholangiopancreatography - No Intervention have been used other than standard of care
Description: No intervention has been used and this is an observational study
Study NCT02382978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nurse-provided well child visit
Study NCT01353924 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bet v 1aF1-Alum + Bet v 1aF2-Alum
Description: subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year
Study NCT01353924 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Alum-Placebo
Description: subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
Study NCT02356081 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASyMS intervention Group
Description: ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
Study NCT01224210 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ambrisentan
Description: Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
Study NCT01637961 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Given PO
Study NCT01637961 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03418077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy Drink
Description: Participants will consume a randomly assigned single 24 oz can of an original flavor energy drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
Study NCT03418077 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-control
Description: Participants will consume a randomly assigned single 24 oz can of control drink within a 30-minute period. Baseline ECG, HR, BP, blood sample and body weight will be obtained. Then perform a continuous, progressive treadmill or bicycle ergometry test until volitional exhaustion. ECG will be monitored continuously during exercise, rating of perceived exertion (RPE) will be recorded every minute of each workload increase. After completion of exercise, subject will remain standing on treadmill (or seated on ergometer) for 10 minutes while ECG, BP, HR and blood samples are obtained. Subsequent ECG measures will be obtained at 1,4,7 and 10 minutes. After 10 minutes, the subjects will be free to sit, stand or move quietly in the lab. During the 2-hour post exercise monitoring period, subject's ECG, HR, BP will be recorded at 30-minute intervals. Blood samples will be collected immediate upon cessation of exercise, at 1 and 2 hours post exercise
Study NCT01517334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline HCl Microspheres
Study NCT01159769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)
Description: Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
Study NCT04733131 — intervention group
Intervention type: DRUG
Intervention: Conversion to a belatacept regimen
Description: belatacept intravenous on Days 1, 15, 29, 43, 57 then every 28 days.
Study NCT02947282 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Workshop
Description: They will attend a 2 hour class on pelvic floor health
Study NCT01846247 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care + VEM
Description: Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
Study NCT01846247 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care
Study NCT01140269 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PCR test
Description: PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
Study NCT00931567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous platelets gel
Description: Application of autologous platelets gel (Platelet Rich Fibrin) after the  open palm  surgical treatment of Dupuytren's disease.
Study NCT00931567 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaselitulle
Description: application of standardized wound dressing after the  open palm  surgical treatment of Dupuytren's disease.
Study NCT01146730 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workcoping and IPS
Description: Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
Study NCT04122300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euphrasia Officinalis Preparation
Description: At inclusion, before the start of the therapy, a bacterial/viral and chlamydial conjunctival swab is conducted. Afterwards, both eyes of neonates are washed four times a day (i.e., every six hours) with NaCl 0.9%. Subsequently, a drop of Euphrasia is placed into the lower conjunctival sac of each eye, and followed by a lacrimal sac digital massage. If no ocular discharge is apparent for over 24 hours, the therapy is stopped. In case of worsening of symptoms or a positive swab without any improvement of symptoms an antibiotic therapy is initiated: tobramycin (Tobrex 0.3% eye drops, Novartis Pharma Switzerland). An additional swab is performed at 96 hours (i.e. at the end of the study).
Study NCT01146730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary care by GP or NAV
Description: Ordinary care by the participants physician or the local Labour and Welfare Administration
Study NCT01677442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: no-intubated thoracic epidural anesthesia
Description: VATS under no-intubated thoracic epidural anesthesia
Study NCT01677442 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: double-lumen endotracheal intubated anesthesia
Description: VATS under double-lumen endotracheal intubated anesthesia
Study NCT01735591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, 1 capsule a day from inclusion until the date of liver transplantation
Study NCT01735591 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Capsules with 3x10\^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
Study NCT01335243 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Transforaminal Lumbar Interbody Fusion (TLIF) surgery
Description: The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
Study NCT00650559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chest wall enlargement
Description: Widening sternotomy
Study NCT03610178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life-style modification, insulin therapy if needed
Description: All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.1 mmol/L fasting and \<7.0 mmol/L postprandial) are not achieved insulin therapy is started
Study NCT03610178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Life-style modification, insulin therapy if needed
Description: All patients are assigned to life-style modification (diet and physical exercise). If target glucose levels (\<5.3 mmol/L fasting and \<7.8 mmol/L postprandial) are not achieved insulin therapy is started
Study NCT04959110 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic study
Description: * Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L~* Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium~* In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter
Study NCT02980367 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Surgical Management (Rehabilitation)
Description: Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
Study NCT03103659 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: personalised care plan
Description: Quality of life assessement in elderly cancer patients
Study NCT01918111 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter
Study NCT01918111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adenosine infusion treatment
Description: Continue hypertensive medication
Study NCT04595227 — intervention group
Intervention type: DEVICE
Intervention: Computerized pupillary light reflex assessment device
Description: CPLRAD may serve as an effective screening tool for glaucomatous optic neuropathy, since they can dynamically detect abnormal pupillary responses from a novel sequence of light stimuli and functionally-shaped stimuli. CPLRAD can collect the clinical examination data and objectively measure the pupil dynamic parameters monocularly and/or binocularly as indicators from the retina and optic nerve in glaucoma patients.
Study NCT03306602 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Filtek Bulk Fill Posterior Restorative
Description: Filtek™ Bulk Fill Posterior Restorative is a one-step bulk placement solution for fast and easy posterior resin restorations.
Study NCT03306602 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Filtek Z350 XT
Description: Filtek Z350XT is a material for incremental layered composite resin restorations
Study NCT02980367 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Management (Reconstruction)
Description: All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
Study NCT02499549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cocamide diethanolamine
Description: 10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only
Study NCT00325494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MORAb-009
Description: Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m\^2 up to 400 mg/m\^2.
Study NCT04387110 — intervention group
Intervention type: DRUG
Intervention: Ocrelizumab
Description: Receiving either 1infusion (600mg) or 2 infusions (300mg).
Study NCT01325532 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active CES
Description: CES current
Study NCT01325532 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CES
Description: Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
Study NCT00949390 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Survey given at appointment time, then dropped in specified box anonymously.
Study NCT01558531 — intervention group
Intervention type: DEVICE
Intervention: DEB
Description: paclitaxel-eluting balloon angioplasty
Study NCT01558531 — intervention group
Intervention type: DEVICE
Intervention: POBA
Description: conventional balloon angioplasty
Study NCT03786510 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Control group received a personalized advice on lifestyle modification to prevent dementia and usual care of Community Center for Dementia.
Study NCT03786510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive + Maintenance program
Description: Both intensive and maintenance program~1. Intensive program The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching.~2. Maintenance program The allocated study assistants monthly check-up whether participants adhere to the altered habits or not, based on the workbook
Study NCT03786510 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive program only
Description: Only the intensive program was conducted.~The 4-week group-based intensive program was comprised of eight sessions; each session consisted of (1) a 30-min review of the tasks, (2) a 50-min training period, and (3) a 10-min meeting to assign tasks on an individual basis. A study nurse-guided training for modification of vascular risk factors, diet, cognitive and social activity were conducted, And, a physiotherapist conducted an exercise training mainly composed of muscle strengthening and stretching.
Study NCT00482287 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MTR105
Description: Intravenous administration, dose escalating (4 arms), single dose
Study NCT03739359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nasal cannula gas flow
Description: High flow nasal cannula (HFNC) is a relatively new oxygen device, which provides warmed and humidified oxygen for patients. When patients need to inhale aerosolized medication during HFNC, the nebulizer will be placed in-line in order to provide both treatments. This study will investigate the influence of three flow settings (50 L/min, GF:IF=1, GF:IF=0.5) on the clinical effects of nebulization.
Study NCT03739359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nasal cannula gas flow
Description: High flow nasal cannula (HFNC) is a relatively new oxygen device, which provides warmed and humidified oxygen for patients. When patients need to inhale aerosolized medication during HFNC, the nebulizer will be placed in-line in order to provide both treatments. This study will investigate the influence of three flow settings (50 L/min, GF:IF=1, GF:IF=0.5) on the clinical effects of nebulization.